BRPI0814220A2 - Purificação de fator viii usando uma resina multimodal ou de modo misto - Google Patents

Purificação de fator viii usando uma resina multimodal ou de modo misto

Info

Publication number
BRPI0814220A2
BRPI0814220A2 BRPI0814220-3A2A BRPI0814220A BRPI0814220A2 BR PI0814220 A2 BRPI0814220 A2 BR PI0814220A2 BR PI0814220 A BRPI0814220 A BR PI0814220A BR PI0814220 A2 BRPI0814220 A2 BR PI0814220A2
Authority
BR
Brazil
Prior art keywords
multimodal
mixture resin
recombinant
viii
factor purification
Prior art date
Application number
BRPI0814220-3A2A
Other languages
English (en)
Inventor
Susanne Bang
Lars Thim
Johan Karlsson
Original Assignee
Novon Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novon Nordisk As filed Critical Novon Nordisk As
Publication of BRPI0814220A2 publication Critical patent/BRPI0814220A2/pt
Publication of BRPI0814220B1 publication Critical patent/BRPI0814220B1/pt
Publication of BRPI0814220B8 publication Critical patent/BRPI0814220B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
BRPI0814220A 2007-07-11 2008-07-11 purificação de fator viii usando uma resina multimodal ou de modo misto BRPI0814220B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07112287.3 2007-07-11
EP07112287 2007-07-11
PCT/EP2008/059094 WO2009007451A1 (en) 2007-07-11 2008-07-11 Purification of factor viii using a mixed-mode or multimodal resin

Publications (3)

Publication Number Publication Date
BRPI0814220A2 true BRPI0814220A2 (pt) 2015-01-06
BRPI0814220B1 BRPI0814220B1 (pt) 2019-09-17
BRPI0814220B8 BRPI0814220B8 (pt) 2021-05-25

Family

ID=38472947

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814220A BRPI0814220B8 (pt) 2007-07-11 2008-07-11 purificação de fator viii usando uma resina multimodal ou de modo misto

Country Status (15)

Country Link
US (1) US8399620B2 (pt)
EP (1) EP2167526B1 (pt)
JP (1) JP5323072B2 (pt)
KR (1) KR101293504B1 (pt)
CN (1) CN101730707B (pt)
AT (1) ATE503763T1 (pt)
AU (1) AU2008274195B2 (pt)
BR (1) BRPI0814220B8 (pt)
CA (1) CA2692814A1 (pt)
DE (1) DE602008005885D1 (pt)
ES (1) ES2364118T3 (pt)
NL (1) NL300663I2 (pt)
PL (1) PL2167526T3 (pt)
RU (1) RU2493163C2 (pt)
WO (1) WO2009007451A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
US8277649B2 (en) 2009-12-14 2012-10-02 General Electric Company Membranes and associated methods for purification of antibodies
CA2790786C (en) * 2010-02-24 2019-09-24 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
KR101951446B1 (ko) 2010-03-30 2019-02-22 옥타파마 아게 성장 인자 단백질을 정제하는 방법
WO2011121020A1 (en) 2010-03-30 2011-10-06 Octapharma Ag A process for purifying vitamin k dependent proteins such as coagulation factor ix
BR112013007237A2 (pt) 2010-11-05 2016-06-14 Hoffmann La Roche ''método para produzir um anticorpo anti-ig-1r''
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
WO2013075740A1 (en) 2011-11-23 2013-05-30 Sanofi Antibody purification method
WO2014066471A1 (en) 2012-10-24 2014-05-01 Genzyme Corporation Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers
US10188965B2 (en) 2012-12-05 2019-01-29 Csl Behring Gmbh Hydrophobic charge induction chromatographic depletion of a protein from a solution
US20140154233A1 (en) 2012-12-05 2014-06-05 Csl Limited Method of purifying therapeutic proteins
CN103396494B (zh) * 2013-04-27 2015-04-01 江苏省疾病预防控制中心 一种凝血因子ix的单克隆抗体
EP3301115B1 (en) * 2013-05-06 2021-11-10 Sanofi Continuous multistep process for purifying antibodies
RU2017101727A (ru) * 2014-06-25 2018-07-25 ДжейЭйчЭл БИОТЕК, ИНК. Способы и реагенты для очистки белков
CN106687126B (zh) 2014-08-04 2020-07-28 杰特有限公司 因子viii制剂
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
GB201506113D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
GB201506117D0 (en) 2015-04-10 2015-05-27 Ge Healthcare Bio Sciences Ab Method for chromatography
EP3205665A1 (en) * 2016-02-11 2017-08-16 Octapharma AG Method of separating factor viii from blood products
GB201617240D0 (en) * 2016-10-11 2016-11-23 Profactor Pharma Ltd Purification process
US11299533B2 (en) 2017-06-23 2022-04-12 Takeda Pharmaceutical Company Limited Purification of factor VIII subspecies
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302006D0 (sv) * 1992-10-02 1993-06-11 Kabi Pharmacia Ab Protein formulation
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE503424C2 (sv) 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
IL157309A0 (en) 2003-08-07 2004-02-19 Applied Research Systems Method for the purification of a non-immunoglobulin protein
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
EP1707634A1 (en) * 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP2300497B1 (en) 2008-06-24 2012-08-08 Octapharma AG A process of purifying coagulation factor viii

Also Published As

Publication number Publication date
RU2010103528A (ru) 2011-08-20
NL300663I2 (pt) 2016-09-22
PL2167526T3 (pl) 2011-09-30
BRPI0814220B1 (pt) 2019-09-17
EP2167526A1 (en) 2010-03-31
US8399620B2 (en) 2013-03-19
CN101730707A (zh) 2010-06-09
CN101730707B (zh) 2014-12-17
WO2009007451A1 (en) 2009-01-15
CA2692814A1 (en) 2009-01-15
JP2010533150A (ja) 2010-10-21
ATE503763T1 (de) 2011-04-15
AU2008274195B2 (en) 2013-09-05
RU2493163C2 (ru) 2013-09-20
EP2167526B1 (en) 2011-03-30
KR101293504B1 (ko) 2013-08-07
ES2364118T9 (es) 2014-05-19
KR20100051620A (ko) 2010-05-17
JP5323072B2 (ja) 2013-10-23
ES2364118T3 (es) 2011-08-25
BRPI0814220B8 (pt) 2021-05-25
DE602008005885D1 (de) 2011-05-12
AU2008274195A1 (en) 2009-01-15
US20100204452A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
BRPI0814220A2 (pt) Purificação de fator viii usando uma resina multimodal ou de modo misto
EP4524148A3 (en) Anti-vegf protein compositions and methods for producing the same
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
TW200716674A (en) Anti-GM-CSF antibodies and uses therefor
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
MXPA05012316A (es) Peptidos novedosos que se unen al receptor de la eritropoyetina.
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
WO2008074839A3 (en) Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
WO2020198264A8 (en) Modified cleavases, uses thereof and related kits
WO2010129304A3 (en) Method for making heteromultimeric molecules
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
GEP20135917B (en) Stabilized polypeptide compositions
BRPI0513029A (pt) método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
WO2010142551A3 (en) Single variable domain (vhh) antibodies to cytokines of the il-17 receptor family
MX2010002769A (es) Preparacion recombinante de fracciones de bromelaina seleccionadas.
WO2020198683A8 (en) Heteromultimeric proteins and methods of use thereof
ZA202110285B (en) Antibodies and methods of use
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
WO2004094651A3 (en) Novel human polypeptides encoded by polynucleotides
WO2010040736A3 (en) Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
WO2010011994A3 (en) Polypeptides and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/09/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2678 DE 03-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.